126 related articles for article (PubMed ID: 20653081)
1. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
[TBL] [Abstract][Full Text] [Related]
7. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer.
Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424
[TBL] [Abstract][Full Text] [Related]
8. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
9. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
14. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF.
Mueller H; Detjen AK; Schuck SD; Gutschmidt A; Wahn U; Magdorf K; Kaufmann SH; Jacobsen M
Cytokine; 2008 Aug; 43(2):143-8. PubMed ID: 18603443
[TBL] [Abstract][Full Text] [Related]
16. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
18. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
[TBL] [Abstract][Full Text] [Related]
19. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
Gao J; Huang S; Li M; Luo R; Wang X; Takashima A
Vaccine; 2006 Jun; 24(25):5265-8. PubMed ID: 16713660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
